Boston Scientific submits final Liberté PMA module

Interventional device developer Boston Scientific has submitted the final module of a premarket approval (PMA) application to the Food and Drug Administration (FDA) for its Taxus Liberté paclitaxel-eluting coronary sent system.

The third and final module contains nine-month data from the ATLAS clinical trial, according to the Natick, MA-based firm.

By AuntMinnie.com staff writers
March 9, 2006

Related Reading

Boston Scientific notifies EC of Guidant takeover, February 24, 2006

Boston Scientific shows 2005 sales gains, February 7, 2006

Boston Scientific raises Guidant offer, January 17, 2006

Abbott amends Boston Scientific agreement, January 17, 2006

Boston Scientific ups Guidant bid, January 13, 2006

Copyright © 2006 AuntMinnie.com

Page 1 of 181
Next Page